The UTHealth Houston School of Public Health, which operates out of three buildings currently, will consolidate all of its operations in the new building. Rendering courtesy of UTHealth

UTHealth Houston School of Public Health broke ground Tuesday on a new tower in the Texas Medical Center's Helix Park.

The $229 million facility is slated to be open in time for the fall semester in 2026. It will be home to research laboratories, distance-learning technology, an auditorium, teaching kitchen, collaborative spaces, and classrooms and adds 350,000 square feet to TMC’s Helix Park, which has several projects underway.

The UTHealth Houston School of Public Health, which operates out of three buildings currently, will consolidate all of its operations in the new building at 1930 Old Spanish Trail. Disciplines taught in the new tower will include epidemiology, genetics, nutrition, health policy, data science, and health promotion.

According to a statement from UTHealth, the facility will allow the school to continue to grow as enrollment has increased 27 percent over the last five years.

“The new building reflects our bold thinking as we pioneer radical solutions for imminent and future public health challenges while giving our students the tools and resources to improve the health of Texas,” Eric Boerwinkle, dean of UTHealth School of Public Health, said in a statement.

Houston-based Kirksey Architecture and Detroit-based Smith Group designed the new 10-story building which incorporates sustainable design. The tower is slated to feature rainwater harvesting for irrigation, an upper-level terrace, holistic teaching garden and a building automation programming. A skybride over Old Spanish Trail will also connect the UTHealth Houston School of Public Health with a plaza that is shared with MD Anderson.

The new tower joins the 12-story Dynamic One project at TMC Helix Park, which is slated to open this year. It will be anchored by Baylor College of Medicine and is the first of the four buildings planned for the 37-acre, five-million-square-foot development, named for the shape of the park and walkway design at the center of the campus.

The TMC3 Collaborative Building will also be located within Helix Park, also slated to open this year. The 250,000-square-foot space will house research facilities for MD Anderson Cancer Center, the Texas A&M University Health Science Center, the University of Texas Health Science Center at Houston, and TMC, as well as VC firms and hedge funds. UTHealth is also slated to move into a portion of that building in September or October.

Helix Park will be one of four districts within the TMC, including the already operating TMC Medical Campus and the TMC Innovation Factory. The TMC BioPort completes the list. The biomanufacturing and medical supplies distribution site is intended to create over 100,000 new job opportunities once completed.
The Dynamic One building in TMC Helix Park is expected to deliver later this year. Rendering via TMC.edu

Rising TMC development names Houston health care institution as anchor tenant

coming soon

TMC Helix Park, formerly known as TMC3, has announced its first anchor tenant.

The Texas Medical Center and Beacon Capital Partners announced that Baylor College of Medicine will be the anchor tenant of the Dynamic One building at TMC Helix Park. The facility is will be the first to deliver of the four TMC Helix Park industry buildings. The Topped off in December, the Dynamic One building is being developed by Beacon in collaboration with Zoë Life Science and is scheduled to open before the end of the year.

“Beacon is excited that Dynamic One will be our first entry into the fast-growing Houston Life Science market,” says Fred Seigel, president and CEO of Beacon, in a news release. “This state-of-the-art environment is designed to enable and encourage collaboration and will greatly accelerate the innovative lifesaving discoveries that emerge when industry and academic research work side-by-side.”

Baylor College of Medicine will lease 114,000 square-feet of lab and office space in the 355,000-square-foot building. BCM's goal is to house lab space for novel diagnostics and therapeutics — and provide space to house startups.

The organization is expanding its presence in Houston after decades of residing in the region.

“Baylor College of Medicine moved to Houston in 1943 and was the first institution built in the Texas Medical Center," says Dr. Paul Klotman, president and CEO and executive dean of Baylor, in the release. "Our researchers and scientists will have the opportunity to access the uniquely concentrated research environment being developed at TMC Helix Park, facilitating the continuing advancement of innovation and compassionate care."

TMC Helix Park, which includes more than 5 million-square-feet of space across 37-acres, also expects to deliver its research facility, the TMC3 Collaborative Building, later this year.

“Baylor College of Medicine is a major force in life sciences discovery and commercialization at TMC," says Bill McKeon, president and CEO of TMC, in the release. "Their move to TMC Helix Park will serve as a catalyst for enhanced collaboration with TMC’s other esteemed Institutions, as well as with industry leaders from around the world."

BCM is the first anchor tenant announced for TMC Helix Park. Rendering via TMC.edu

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

New UH survey reveals concerns over AI data center growth in Houston

data findings

A new report out of the University of Houston shows that area residents remain wary of the long-term effects of operating data centers.

The recent survey from the University of Houston’s latest SPACE City Panel, conducted by the Center for Public Policy at the Hobby School of Public Affairs, shows that while 85 percent of Houston-area residents use AI, nearly 63 percent oppose the construction of AI data centers within 1 mile of their homes.

Respondents’ concerns centered around data centers’ high energy demand and the area’s power grid reliability. According to the survey, 32 percent of residents who oppose local data center projects would be more likely to support the centers if they relied on renewable energy over fossil fuels.

“Respondents understand that AI can bring economic and educational benefits, but they are also concerned about the physical infrastructure needed to fuel AI, especially data centers,” Soran Mohtadi, post-doctoral fellow at the Hobby School and a researcher on the report, said in a news release. “This physical infrastructure demands more electricity and water, leading to environmental impacts.”

Experts estimate that 6.5 gigawatts of data center capacity will be added to the Texas grid by 2030. And Houston’s data center capacity is predicted to more than double by 2028.

The Electric Reliability Council of Texas also projects electricity demand could reach 218 gigawatts by 2031, which would be more than double the record peak set in August 2023. Data centers are expected to account for 86 gigawatts of that new demand.

Survey respondents also said they are concerned about the state's future water supply, given the large amounts of water that data centers need to stay cool.

In terms of who’s responsible for that issue, 57.6 percent of respondents said they put the onus on Texas lawmakers, while 31.5 percent say tech companies should be responsible.

Additionally, more than 75 percent of respondents believed that data center developers and technology companies—not residents—should bear the cost of infrastructure upgrades to support data centers.

“Every decision legislators make has implications on residents’ everyday lives and local infrastructure now and in the future,” Maria P. Perez Arguelles, lead researcher on the report and research assistant professor at the Hobby School, added in the news release. “This issue is going to become more important in years to come, so this is just the beginning.”

Read the full report here.

Houston-born Cemvita makes breakthrough in sustainable fuel production

clean fuels

Houston-based biotech company Cemvita announced that it recently reached a critical milestone in the development of its FermOil product, which can be used to create Sustainable Aviation Fuel (SAF) and other renewable fuels at industrial scale.

The company shared in a news release that it completed a 75,000-liter industrial fermentation run at Belgium's Bio Base Europe Pilot Plant.

The campaign achieved target technical metrics for the production of FermOil, Cemvita’s renewable natural oil (RNO). FermOil is produced from industrial crude glycerin, an industrial byproduct, as opposed to traditional sugar-based feedstocks used in many bio-oil fermentation processes. It's designed to be a drop-in feedstock for creating SAFs.

Cemvita had previously advanced its FermOil production process through multiple scale-up stages before successfully reaching the 75,000-liter demonstration campaign, according to the company.

“This is not just a fermentation milestone,” Moji Karimi, CEO at Cemvita, said in the release. “It is a blueprint for how existing industrial infrastructure can evolve into circular bioeconomy infrastructure. Every biodiesel plant generating crude glycerin is a potential platform for renewable natural oil production.”

The milestone also supports the deployment of Cemvita’s industrial biomanufacturing platform, FermWorks, which integrates with existing energy and industrial infrastructure to turn waste carbon streams into SAFs and other materials. According to the release, Cemvita plans to move forward with commercial deployment discussions with partners in Brazil, Europe and in the UK. Cemvita already has a partnership with the Brazilian sustainable research institution REMA.

“We are proud to support innovative companies like Cemvita in scaling breakthrough industrial biotechnology solutions,” Hendrik Waegeman, head of business operations at Bio Base Europe Pilot Plant, added in the release. “Successfully operating at the 75,000-liter scale using a feedstock such as crude glycerin highlights both the maturity of the technology and the quality of the scale-up execution achieved by the Cemvita team.”

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Eli Lilly scoops up Houston biotech startup in $300 million deal

big pharma deal

Pharmaceutical giant Eli Lilly has acquired Houston biotech startup CrossBridge Bio, which develops antibody-drug conjugates for cancer, in a deal worth up to $300 million. The deal was celebrated by TMC Venture Fund and the University of Texas Health Science Center at Houston last week.

CrossBridge, founded in 2023, is developing ADCs based on research by Kyoji Tsuchikama and Zhiqiang An, both of UT Health Houston. Tsuchikama is an associate professor of medicinal chemistry and a globally recognized ADC pioneer, and An is a professor of molecular science and vice president of drug discovery.

Antibody-drug conjugates (ADCs) are a potent combination of targeted therapy and chemotherapy that kills cancer cells while saving healthy tissue.

Clinical trials for CrossBridge’s primary ADC candidate, CBB-120, are expected to start this year, pending approval from the U.S. Food and Drug Administration (FDA).

“I’m proud of how well our team has executed and advanced our platform in such a short time since the company’s founding,” Michael Torres, co-founder and CEO of CrossBridge, said in a news release. “By becoming a part of Lilly, a leader in patient-focused therapeutic development, we are well-positioned to further accelerate the clinical potential of this approach.”

Under the Lilly deal, CrossBridge shareholders were expected to receive an upfront payment along with a follow-up payment based on the achievement of certain milestones.

In 2024, CrossBridge closed a $10 million seed round. Among the investors in CrossBridge are the Texas Medical Center Venture Fund, CE-Ventures, Alexandria Venture Investments, Portal Innovations, Linden Lake Labs, and the Cancer Prevention and Research Institute of Texas (CPRIT). It was formed in TMC Innovation’s Accelerator for Cancer Therapeutics program."Built within the TMC ecosystem, CrossBridge Bio grew with the support, funding, and resources that helped shape its trajectory. TMC led the company's early financing and watched it evolve from its earliest days to its acquisition by Eli Lilly," William McKeon, president and CEO of the Texas Medical Center, shared in a LinkedIn post. "[This is a] strong reminder that breakthrough science and the right early backing can change what’s possible."